Back to TAKView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
Drug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA4/24/2017
Natpar
Natpar is indicated as adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.
OrphanConditional
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
REPLAGALPhase 3
Fabry Disease
Alogliptin and pioglitazonePhase 3
Type 2 Diabetes Mellitus
HYQVIAPhase 3
Primary Immunodeficiency Diseases (PID)
IGSC 20% infusionPhase 3
Primary Immunodeficiency Disease
Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.Phase 3
Hypertension
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts